Biologicals and bone loss

Por Lems, Willem F
Publicado em 2012

Glucocorticoids: bad or safe for the bones?

Por Lems, Willem F
Publicado no RMD Open (2015)

Osteoimmunology and osteoporosis

Por Geusens, Piet, Lems, Willem F
Publicado em 2011

Bisphosphonates and glucocorticoid-induced osteoporosis: cons

Por Lems, Willem F., Saag, Kenneth
Publicado no Endocrine (2015)

Measuring metacarpal cortical bone by digital x-ray radiogrammetry: a step forward?

Por Geusens, Piet P, Lems, Willem F
Publicado em 2009

Exercise-induced changes in interleukin-10 in patients with knee osteoarthritis: new perspectives?

Por Lems, Willem F, den Uyl, Debby
Publicado em 2010

Are we ready for therapeutic drug monitoring of biologic therapeutics?

Por Krieckaert, Charlotte LM, Lems, Willem F
Publicado em 2011

Biologicals and bone loss

Por Krieckaert, Charlotte L.M., Lems, Willem F.
Publicado em 2012

Systemic lupus erythematosus and fractures

Por Bultink, Irene E M, Lems, Willem F
Publicado no RMD Open (2015)

Measurement of stiffness in patients with rheumatoid arthritis in low disease activity or remission: a systematic review

Por van Tuyl, Lilian HD, Lems, Willem F, Boers, Maarten
Publicado em 2014

Advances in Glucocorticoid-Induced Osteoporosis

Por den Uyl, Debby, Bultink, Irene E. M., Lems, Willem F.
Publicado em 2011

Response to ‘Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis’ – authors’ reply

Por Markusse, Iris M., Lems, Willem F., Huizinga, Tom W.J., Allaart, Cornelia F.
Publicado no Arthritis Res Ther (2015)

Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular r...

Por Scarpignato, Carmelo, Lanas, Angel, Blandizzi, Corrado, Lems, Willem F, Hermann, Matthias, Hunt, Richard H
Publicado no BMC Med (2015)

Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice

Por Eekman, Danielle A, Bultink, Irene EM, Heijboer, Annemieke C, Dijkmans, Ben AC, Lems, Willem F
Publicado em 2011

(Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosi...

Por den Uyl, Debby, Nurmohamed, Mike T, van Tuyl, Lilian HD, Raterman, Hennie G, Lems, Willem F
Publicado em 2011

Inflammatory Rheumatic Disorders and Bone

Por Bultink, Irene E. M., Vis, Marijn, van der Horst-Bruinsma, Irene E., Lems, Willem F.
Publicado em 2012

Proteasome inhibitors as experimental therapeutics of autoimmune diseases

Por Verbrugge, Sue Ellen, Scheper, Rik J, Lems, Willem F, de Gruijl, Tanja D, Jansen, Gerrit
Publicado no Arthritis Res Ther (2015)

Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates

Por Dijkmans Ben AC, Derikx Harm JGM, Bultink Irene EM, Vis Marijn, Eekman Danielle A, Lems Willem F
Publicado em 2009-07-01

Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates

Por Eekman, Danielle A, Vis, Marijn, Bultink, Irene EM, Derikx, Harm JGM, Dijkmans, Ben AC, Lems, Willem F
Publicado em 2009

Assessment of Individual Fracture Risk: FRAX and Beyond

Por van den Bergh, Joop P. W., van Geel, Tineke A. C. M., Lems, Willem F., Geusens, Piet P.
Publicado em 2010